



PRESS RELEASE

Syndivia receives €2m Deeptech financing from Bpifrance to advance its lead immunoconjugate for solid cancers.

Strasbourg, France, Mar 10, 2020 – Syndivia, a research-driven biotechnology company focused on the development of new therapeutic modalities for cancers, announced today that it will benefit from €2 m deep tech financing from Bpifrance. Proceeds will be used to further fund the advancement of one company’s drug candidate towards the clinic.

The Deeptech plan was initiated by the French government and has been deployed by Bpifrance since 2019 to support deep tech startups resulting from research based on breakthrough innovations. The main objective is to allow these companies to grow, and to stimulate innovation by strengthening the links between academia and the entrepreneurial world.

Sasha Koniev, CEO of Syndivia, said, “We are very grateful to Bpifrance for this generous support. This financing will largely accelerate the development of our lead immunoconjugate for various cancer indications, which to date have a very limited number of effective treatment options.”

Commenting on this news, Alban Stamm, in charge of innovation at Bpifrance, said, “Syndivia, which initially emerged from the research of academic laboratories supported by SATT Conectus and reinforced with iLab 2014 (emergence) and 2015 (development) grants, succeeded in bringing together all the ingredients to meet technological challenges. At Bpifrance, we appreciate Syndivia’s progress to date and especially value the team: initially composed of young researchers with strong entrepreneurial capacity, it surrounded itself with an experienced board bringing together all the key success factors of a biotech startup.”

About Bpifrance

Bpifrance is the French national investment bank. It finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services such as training and consultancy to help entrepreneurs meet their challenges.

www.bpifrance.com

About Syndivia

Syndivia is a biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a specific targeting of the tumor microenvironment and anatomical hallmarks of solid tumors. Syndivia’s mission is to develop new therapies for patients with the most difficult-to-treat cancer indications.

www.syndivia.com

Media Contact

Syndivia

Sasha Koniev, CEO

Phone: 00 33 3 67 10 42 20

Email: enquiry@syndivia.com